T1	Participants 410 419	Australia
T2	Participants 424 429	China
T3	Participants 1033 1096	102 protocol compliant Brisbane recipients of VLP immunotherapy
T4	Participants 1689 1764	168 Wenzhou protocol compliant subjects who also received VLP immunotherapy
T5	Participants 1920 1990	genital warts in patients for whom destructive therapy is unsuccessful
